FBR Capital Reiterates Their Buy Rating on Acceleron Pharma

FBR Capital analyst Edward White reiterated a Buy rating on Acceleron Pharma (NASDAQ: XLRN) yesterday. The company’s shares opened today at $27.10.

According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -5.0% and a 41.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and RXi Pharmaceuticals Corp.

Currently, the analyst consensus on Acceleron Pharma is Moderate Buy and the average price target is $35.67, representing a 31.6% upside.

In a report issued on May 8, Oppenheimer also reiterated a Buy rating on the stock with a $40 price target.

Based on Acceleron Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.71 million and GAAP net loss of $25.41 million. In comparison, last year the company earned revenue of $18.2 million and had a net profit of $5.06 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to promote red blood cell production; dalantercept, for the treatment of patients with renal cell carcinoma; and ACE-083, designed for the treatment of focal muscle disorders. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.

Leave a Reply

Your email address will not be published. Required fields are marked *